Innate Pharma to Host Key Opinion Leader Discussion on the Potential Role of Lacutamab Across T-Cell Lymphomas
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq:
” or the “Company
today announced that it will host a virtual key opinion leader
(KOL) discussion focused on the potential role of its lead
investigational drug candidate, lacutamab, an anti-KIR3DL2
cytotoxicity-inducing antibody in development for T-cell lymphomas.
The event will be held virtually on Tuesday, February 9, 2021 at
2:00 p.m. CET / 8:00 a.m. ET.
The event will feature presentations from the
Company’s executive leadership team, as well as the following
- Pierluigi Porcu,
M.D., Professor of Medical Oncology, Dermatology and
Cutaneous Biology and Director, Division of Hematologic
Malignancies and Hematopoietic Stem Cell Transplantation at Thomas
Jefferson University, US; Principal Investigator of Innate’s Phase
2 TELLOMAK clinical trial, which is evaluating lacutamab in mycosis
fungoides and Sézary syndrome; and
- Olivier Hermine,
M.D., Professor of Hematology at the University of Paris
Descartes and Director, Division of Adult Hematology at Hôpital
Universitaire Necker Enfants Malades, Member of the Académie des
Sciences, Member of the Lymphoma Study Association (LYSA),
Presenters will provide an overview of the
treatment landscape and prevalence of the lacutamab target,
KIR3DL2, across subtypes of T-cell lymphoma. They will also
highlight the potential impact of lacutamab in current and upcoming
clinical programs in cutaneous and peripheral T-cell lymphomas.
Details for the Virtual
The live webcast of the event will be available
at the following link:
A telephone number will also be made available.
Participants may register in advance of the event at
registration, participants will be provided with dial-in numbers, a
direct event passcode and a unique registrant ID that they may use
10 minutes prior to the event start to access the call. Call
reminders will also be sent to registered participants via e-mail
the day prior to the event.
A replay of the webcast will be archived on
Innate’s website for 90 days following the event.
This information can also be found in the
Investors section of the Innate website, www.innate-pharma.com.
(IPH4102) is a first-in-class anti-KIR3DL2 humanized
cytotoxicity-inducing antibody, which is currently in clinical
trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan
disease. This group of rare cutaneous lymphomas of T lymphocytes
has a poor prognosis with few efficacious and safe therapeutic
options at advanced stages.
KIR3DL2 is an inhibitory receptor of the KIR
family, expressed by approximately 65% of patients across all CTCL
subtypes and expressed by up 90% of patients with certain
aggressive CTCL subtypes, in particular, Sézary syndrome. It is
expressed by up to 50% of patients with peripheral t-cell lymphoma
(PTCL). It has a restricted expression on normal tissues.
About Innate Pharma:
Innate Pharma S.A. is a global, clinical-stage
oncology-focused biotech company dedicated to improving treatment
and clinical outcomes for patients through therapeutic antibodies
that harness the immune system to fight cancer.
Innate Pharma’s broad pipeline of antibodies
includes several potentially first-in-class clinical and
preclinical candidates in cancers with high unmet medical need.
Innate has been a pioneer in the understanding
of natural killer cell biology and has expanded its expertise in
the tumor microenvironment and tumor-antigens, as well as antibody
engineering. This innovative approach has resulted in a diversified
proprietary portfolio and major alliances with leaders in the
biopharmaceutical industry including Bristol-Myers Squibb, Novo
Nordisk A/S, Sanofi, and a multi-products collaboration with
Based in Marseille, France, Innate Pharma is
listed on Euronext Paris and Nasdaq in the US.
Learn more about Innate Pharma at
Information about Innate Pharma
FR0010331421Euronext: IPH Nasdaq: IPHA9695002Y8420ZB8HJE29
Disclaimer on forward-looking
information and risk factors:
This press release contains certain
forward-looking statements, including those within the meaning of
the Private Securities Litigation Reform Act of 1995.The use of
certain words, including “believe,” “potential,” “expect” and
“will” and similar expressions, is intended to identify
forward-looking statements. Although the company believes its
expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those anticipated. These risks and uncertainties
include, among other things, the uncertainties inherent in research
and development, including related to safety, progression of and
results from its ongoing and planned clinical trials and
preclinical studies, review and approvals by regulatory authorities
of its product candidates, the Company’s commercialization efforts,
the Company’s continued ability to raise capital to fund its
development and the overall impact of the COVID-19 outbreak on the
global healthcare system as well as the Company’s business,
financial condition and results of operations. For an additional
discussion of risks and uncertainties which could cause the
company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque")
section of the Universal Registration Document filed with the
French Financial Markets Authority (“AMF”), which is available on
the AMF website http://www.amf-france.org or on Innate Pharma’s
website, and public filings and reports filed with the U.S.
Securities and Exchange Commission (“SEC”), including the Company’s
Annual Report on Form 20-F for the year ended December 31, 2019,
and subsequent filings and reports filed with the AMF or SEC, or
otherwise made public, by the Company.
This press release and the information contained
herein do not constitute an offer to sell or a solicitation of an
offer to buy or subscribe to shares in Innate Pharma in any
For additional information, please
Tel.: +33 (0)4 30 30 30 email@example.com
MediaInnate Pharma Tracy Rossin
(Global/US)Tel.: +1 240 801
0076Tracy.Rossin@innate-pharma.comATCG Press Marie
Puvieux (France)Tel.: +33 (0)9 81 87 46